ArticleParasites & vectors2026
A retrospective comparison of two-dose and three-dose melarsomine, with doxycycline and a macrocyclic lactone, in 1246 shelter dogs.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDoxycycline and a macrocyclic lactone (ML/doxy) are now standard additions to melarsomine treatment protocols. The safety and efficacy of the two-dose melarsomine protocol have not been revisited since these adjuncts were added to treatment guidelines.
methodsThis was a retrospective cohort study comparing two-dose and three-dose melarsomine in dogs with class 1 and 2 heartworm disease, treated at Miami-Dade Animal Services from 2014 to 2024. All dogs received ML/doxy. Outcome measures were efficacy 5-10 months after the last melarsomine injection, survival to 8 weeks post-melarsomine, and post-treatment complications. Efficacy was assessed for different MLs administered at intake.
resultsDenominators for analyses varied on the basis of available data. There were 889 dogs in the two-dose melarsomine group and 357 in the three-dose group. Follow-up antigen tests were negative in 242/252 dogs (96.0%; confidence interval [CI] 92.9-97.8%) in the two-dose group and 24/24 (100%; CI 86.2-100%) in the three-dose group (P > 0.9999; not significant [NS]). All-cause mortality was 4/491 (0.8%) in the two-dose group and 4/154 (2.6%) in the three-dose group (P = 0.097; NS). Heartworm-related mortality was 1/491 (0.2%) in the two-dose group and remained at 4/154 (2.6%) in the three-dose group (P = 0.013). The deaths in the three-dose group were not considered to be related to the specific treatment protocol. Mild post-melarsomine complications occurred in 66/889 (7.4%) dogs in the two-dose group and 13/357 (3.6%) in the three-dose group (P = 0.014). Severe complications occurred in 3/889 (0.3%) dogs in the two-dose group and 5/357 (1.4%) in the three-dose group (P = 0.047). Two dogs that initially received ivermectin (2/65; 3.1%) and two that received milbemycin (2/35; 5/7%) had a positive follow-up antigen test, compared with none (0/33) for sustained-release moxidectin.
conclusionsThe findings suggest that two-dose melarsomine, with ML/doxy, is a potential alternative to three-dose melarsomine for class 1 and 2 heartworm disease. Moxidectin may be the preferred ML in the two-dose protocol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.